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Sir,
The issue of suitability of therapeutic drug monitoring (TDM)
for imatinib continues to fuel controversies. Unlike two previous
studies in gastrointestinal stromal tumours (GIST) patients (Judson
et al, 2005; Delbaldo et al, 2006), a recent clinical pharmacokinetic
(PK) substudy carried out on the basis of the B2222 trial, evaluating
imatinib in patients with unresectable or metastatic CD117-positive
GIST, found a correlation between imatinib total exposure and
clinical response. Trough levels over 1100ngml
 1 predicted a better
overall benefit rate (composite clinical outcome; Demetri et al,
2009). These results are thus in line with observations made in CML
patients, showing trough levels over 1000ngml
 1 to predict a better
molecular response rate (Picard et al, 2007; Larson et al,2 0 0 8 ) .
These concentration–effect relationships confirm and strengthen
our results obtained in a population of GIST patients, albeit
smaller-sized (38 patients), which we had previously reported in
the Journal (Widmer et al, 2008). We have indeed observed that
higher free imatinib exposure predicts a higher probability of
therapeutic response, when taking into account tumour KIT
genotype. The strongest association was observed in patients
harbouring exon 9 mutation or wild-type (wt) KIT, which is known
to decrease tumour sensitivity towards imatinib (Heinrich et al,
2003). In fact, we found that, in our population of patients, free
plasma concentration (the pharmacologically active species in
plasma; i.e., imatinib fraction not bound to a1-acid glycoprotein
(AGP); Widmer et al, 2006) was a better predictor of the clinical
response rather than total concentration. This free exposure was
derived from the total exposure using a mathematical model taking
into account the AGP plasma level (Widmer et al, 2006). Moreover,
we found a significant relationship between this free exposure and
clinical response only in patients with exon 9 mutation and wt KIT.
Of importance, we also observed significant correlations between
total, as well as free, imatinib exposure and the occurrence of side
effects (Widmer et al, 2008).
To better compare our results with those of the B2222 PK
substudy, we recomputed maximum a posteriori extrapolations for
both total Cmin and free Cmin in our patient samples, rather than
considering the global imatinib exposure (area under the plasma
concentration–time curve) that was previously analysed (Widmer
et al, 2008). Among the 38 GIST patients of the previous analysis,
AGP plasma levels – required to calculate free Cmin – were available
for 36 patients. All these patients were included in an observational
study approved by the Ethics Committee of the Lausanne Faculty
of Medicine. Informed written consent was obtained from all
the participants. A specific population PK model (Widmer et al,
2006) was used for this extrapolation (using NONMEM, version VI
2.0, NONMEM Project Group, University of California at San
Francisco, San Francisco, CA, USA). We investigated their
correlation with clinical benefit, defined as response evaluation
criteria in solid tumours (RECIST) complete response, partial
response or stable disease, by logistic regression analysis (using
Stata version 10.1, Stata Co., College Station, TX, USA).
We found no significant overall association between total Cmin
and response in our GIST population. Conversely, imatinib free
Cmin was correlated with a clinical benefit, with responders having
higher free levels than non-responders (RECIST progressive
disease). This relationship did not reach significance over the
whole patient sample series (i.e., irrespective of the KIT genetic
profile; area under the ROC curve¼0.594 and P¼0.26 using
logistic regression analysis on log2 values of free Cmin). However,
focusing on exon 9 mutated and wt KIT cases allowed the
identification of a clear relationship (area under the ROC curve¼
0.932 and P¼0.013). The cutoff value of 20ngml
 1 free imatinib
plasma trough level corresponded to the best sensitivity (86%) and
specificity (100%). The geometric average estimate of imatinib free
fraction across our study samples was 1.0% (CV 45%). The mean
daily doses of imatinib only tended to be slightly higher in exon 9
or wt KIT patients compared with exon 11 KIT patients (649mg vs
590mg daily, respectively; P¼0.07 using t-test). Table 1 describes
our GIST patient samples and Figure 1 shows the striking
difference between the free Cmin values of responder and non-
responder exon 9 or wt KIT patients (per-sample analysis).
This per-sample analysis was performed because imatinib doses
administered to each patient during the course of this 3-year-long
observational study could be increased or decreased. The concen-
tration, and possibly the response or adverse events related to
treatment, may therefore vary at some point for a given patient.
Interestingly, a similar analysis carried out on a per-patient basis
(i.e., expressing only a single mean free Cmin and one median
response for each individual patient) provided a similar relation- Published online 23 February 2010
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www.bjcancer.comship and cut-off, without, however, reaching statistical significance
because of the limited number of patients with exon 9 or wt KIT.
The results from our observational study should therefore still be
considered cautiously and will have to be confirmed in a larger
patient population. In fact, extrapolation of free concentrations
still remains to be formally confirmed by direct measurement of
free plasma levels of imatinib in patients’ blood, an aspect that is
currently being addressed in ongoing studies initiated at our
Institution with GIST and CML patients.
Altogether, the results from the B2222 substudy and our
results call for attention to imatinib concentration–effect relation-
ships in the management of GIST patients, which deserve further
in-depth exploration. In our opinion, future investigations should
take into account not only total plasma concentrations but also
free plasma concentrations (either measured or computed with
regard to AGP and albumin levels), as well as the tumour genotype.
We are currently expanding our set of observations in a larger
GIST population in that endeavour. We also agree with the authors
of the B2222 PK substudy regarding the urgent need for
prospective controlled trials to assess whether a TDM programme
would optimise the treatment outcomes in GIST patients, as it has
been called for in CML patients (Blasdel et al, 2007). Similar
considerations might apply as well to other new tyrosine kinase
inhibitors currently fleshing out our armament of targeted anti-
cancer agents. Convenient analytical methods already exist for
their measurement in patients’ plasma (Haouala et al, 2009), but,
as for imatinib, further clinical evaluation of their concentration–
response relationships and of the benefit of optimising their
concentration exposure is warranted in cancer patients.
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Table 1 Left part: description of free trough plasma concentrations (free Cmin) deduced from imatinib and AGP levels available in samples from 36 GIST
patients; right part: description of the samples from seven patients with exon 9 or wt KIT identified among 20 with known tumour KIT genotype
All patients (wt, exon 9 and exon 11 KIT) Exon 9 and wt KIT patients
RECIST response
n (blood
samples)
Median free Cmin
and range (ngml
 1)
n (blood
samples)
Median free Cmin
and range (ngml
 1)
Progressive disease 50 13.4 (3.8–22.9) 19 10.1 (6.1–17.4)
Stable disease 63 15.8 (4.5–39.3) 4 19.9 (13.7–20.2)
Partial response 72 13.3 (2.8–33.0) 2 20.5 (14.9–26.1)
Complete response 8 26.0 (25.0–27.0) 8 26.0 (25.0–27.0)
Abbreviations: AGP¼a1-acid glycoprotein; GIST¼gastrointestinal stromal tumour; RECIST, response evaluation criteria in solid tumours. Each patient provided between
1 and 12 samples over 3 years (median: 4 samples per patient), along with current RECIST response status.
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Figure 1 Box plots and individual values of extrapolated free trough
concentrations (free Cmin) in exon 9 mutated or wt KIT patients, contrasting
responders’ samples (complete response, partial response, or stable disease;
n¼14; median¼25.7ngml
 1) vs non-responders’ (progressive disease; n¼19;
median¼10.1ngml
 1).
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